> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Incyte Lifts 2026 Sales Outlook To $5.21 Billion-$5.30 Billion Even As Vega Charge Drives $784.8 Million Quarterly Loss
- URL: https://www.bullished.co/incyte-lifts-2026-sales-outlook-to-5-21-billion-5-30-billion-even-as-vega-charge-drives-e5ecf813/
- Published: 2026-10-29T11:33:18.000Z
- Updated: 2026-10-29T11:33:18.000Z
- Description: A one-time $1.23 billion Vega charge swamped profit, while Opzelura and cancer-drug sales grew and guidance rose.
- Author: Matteo Parrino
- Tags: SEC Filings, INCY, Industry: Healthcare

Incyte, the biopharmaceutical company behind the blood-cancer drug Jakafi and the skin cream Opzelura, raised its 2026 net sales guidance to [$5,210 million to $5,300 million](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000063/incy-q32026xexx991.htm?ref=bullished.co) on Thursday, even as a one-time $1.23 billion charge for buying Vega Therapeutics pushed it to a third-quarter net loss of $784.8 million. The prior range was $5,130 million to $5,260 million.

## Sales up 14%, profit gone

Total revenue in the quarter was $1.56 billion, up 14% from a year earlier, and total net sales were $1.32 billion, also up 14%. Jakafi, the biggest product, brought in $827 million, up 4%, which the company said was driven by a 12% rise in paid demand.

Opzelura cream reached $255 million, up 36%, on higher patient demand in atopic dermatitis and vitiligo plus better net pricing after a line-extension settlement in the second quarter. Hematology and oncology products hit $235 million, up 38%, led by Niktimvo, Zynyz and Monjuvi/Minjuvi.

The bottom line went the other way. Incyte posted a GAAP net loss of $784.8 million, or $3.86 per share, against a $424.2 million profit a year earlier. R&D spending rose to $1.79 billion because of the $1.23 billion Vega charge; without it, R&D grew 11% and GAAP operating income rose 18%.

## Guidance raised across three lines

Opzelura guidance now stands at $1,100 million to $1,120 million, from $1,050 million to $1,100 million. Hematology and oncology moves to $890 million to $910 million, from $860 million to $890 million. Jakafi and expense guidance are unchanged.

Cash and marketable securities were $3.9 billion at September 30, against $3.6 billion at the end of 2025\. CEO Bill Meury said the company has built a "durable core business beyond Jakafi."

## Vega, Medicaid and the pipeline

Incyte completed the Vega purchase in July for $1.25 billion. It brought latarcibart, an antibody in late-stage testing for von Willebrand disease, a bleeding disorder. Star Therapeutics, Vega's parent, can earn up to $750 million more if sales milestones are met.

In August, Incyte agreed with the federal Medicaid agency to let state programs buy Jakafi at prices aligned with a group of other industrialized nations. The company expects that to exempt it from certain future federal pricing mandates, including the proposed GUARD and GLOBE models.

Phase 3 data for povorcitinib in prurigo nodularis and for ruxolitinib cream in hidradenitis suppurativa are due in the fourth quarter, along with a European Commission decision on povorcitinib.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — INCYTE CORP (INCY)](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000063/incy-20261029.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit incy-q32026xexx991.htm — INCYTE CORP 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000063/incy-q32026xexx991.htm?ref=bullished.co) — SEC EDGAR
- [Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?](https://finance.yahoo.com/healthcare/articles/incyte-gears-report-q3-earnings-122500992.html?ref=bullished.co) — Yahoo Finance
- [Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)?](https://finance.yahoo.com/healthcare/articles/does-genmab-trial-deal-change-151613125.html?ref=bullished.co) — Yahoo Finance
- [ESMO: Incyte feels ‘neck and neck’ with RevMed in KRAS G12D race](https://www.fiercebiotech.com/biotech/esmo-why-incyte-sees-itself-neck-and-neck-revmed-kras-g12d-race?ref=bullished.co) — fiercebiotech.com
- [Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration](https://finance.yahoo.com/healthcare/articles/incyte-incy-starts-kras-g12d-131445046.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer](https://www.businesswire.com/news/home/20261024542855/en/Genmab-and-Incyte-Announce-Clinical-Trial-Collaboration-in-Metastatic-Colorectal-Cancer?ref=bullished.co) — businesswire.com